The IGNITE study was a Phase 3b, open-label, randomized study (n=242) that evaluated the use of Contrave (naltrexone HCl and bupropion HCl extended-release tablets) in combination with a commercially-available comprehensive lifestyle intervention program versus usual care in a real-world weight-loss setting. Study patients were obese or overweight adults aged 18–60 years with dyslipidemia and/or controlled hypertension. 

By Week 16, patients treated with Contrave had to achieve ≥5% weight loss to continue therapy. The primary endpoint was the percent change in body weight per protocol population. Secondary endpoints included percentage of patients achieving ≥5%, ≥10%, or ≥15% weight loss.  

Related Articles

At Week 26, the data showed patients treated with Contrave lost significantly more weight vs. usual care patients (9.5% vs. 0.9%; P<0.0001). Significantly more patients treated with Contrave achieved three weight loss thresholds than usual care-treated patients: ≥5% weight loss was seen in 84.5% vs. 12.2%, respectively; ≥10% weight loss was seen in 42.3% vs. 3.7%, respectively; and ≥15% weight loss was seen in 12.7% vs. 0%, respectively. 

In addition, significantly greater reductions in obesity-related factors were seen in patients treated with Contrave vs. usual care, including triglycerides, waist circumference, glucose, insulin, and a measure of insulin resistance. A significantly greater increase in high density lipoprotein (HDL) cholesterol was also seen in patients treated with Contrave. 


Continue Reading

Contrave was approved in September 2014 for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI ≥30kg/m2 or ≥27kg/m2 in the presence of at least one weight-related comorbidity (eg, hypertension, type 2 diabetes mellitus, dyslipidemia). 

For more information visit onlinelibrary.wiley.com.